ライフサイエンスコーパス: glucokinase

1 do not function as allosteric activators of glucokinase.

2 -like domain was identified to interact with glucokinase.

3 xidation/utilization, and phosphorylation by glucokinase.

4 because of inadequate activation of hepatic glucokinase.

5 e the non-Michaelis-Menten behavior of human glucokinase.

6 id not largely differ from that of wild-type glucokinase.

7 e to the apparent absence of a gene encoding glucokinase.

8 hat is 12-fold higher than that of wild-type glucokinase.

9 -PTS activity and expression of the gene for glucokinase.

10 ed for silencing of the key metabolic enzyme glucokinase.

11 -against-all in silico mutagenesis for human glucokinase.

12 (cat)/K(m) value displayed by native E. coli glucokinase.

13 f glucose on the subcellular distribution of glucokinase.

14 s the insulin-sensitive FOXO1 corepressor of glucokinase.

15 he k(cat)/K(m) value of endogenous bacterial glucokinase.

16 ession of Hex-C, a homolog of the MODY2 gene Glucokinase.

17 and the physiological glucose-sensing enzyme glucokinase.

18 low affinity glucose-phosphorylating enzyme glucokinase.

19 stigate the conformational dynamics of human glucokinase, a 52 kDa monomeric enzyme that displays kin

20 have previously been reported to have potent glucokinase-activating properties that exceed the in vit

21 he increase in glucose uptake resulting from glucokinase activation in hepatocytes in vitro translate

22 Arcuate nucleus glucokinase activation may represent a CNS mechanism tha

23 ave been synthesized and tested in vitro for glucokinase activation potential.

24 In contrast, glucokinase activation stimulated Cn-dependent expressio

25 Compound 1, a glucokinase activator (GKA) lead that we have previously

26 A short and practical synthesis of glucokinase activator 1 was achieved utilizing a converg

27 A glucokinase activator acutely restored cytochrome c redu

28 have investigated the acute actions of novel glucokinase activator compound 50 (GKA50) on islet funct

29 f stability, activity index, the response to glucokinase activator drug, and the effect of glucokinas

30 glucokinase activity was increased, using a glucokinase activator drug, or decreased, using RNA inte

31 A pharmacological glucokinase activator produced a dose-related increase i

32 Finally, administration of a small molecule glucokinase activator to old mice doubled the frequency

33 lead to the identification of 19 as a potent glucokinase activator with a greater than 50-fold liver-

34 ycogen synthesis with glucose and insulin or glucokinase activator, which resulted in channeling gluc

35 PKCzeta is required for glucose- and glucokinase activator-induced proliferation of rodent an

36 optimization of a novel series of allosteric glucokinase activators (GKAs).

37 g anti-hyperglycemic agents that function as glucokinase activators (GKAs).

38 nd initial optimization of a novel series of glucokinase activators (GKAs).

39 Systemically acting glucokinase activators (liver and pancreas) have been re

40 Insulin-releasing glucokinase activators and pancreatic-G-protein-coupled

41 ee principal parts of the new small molecule glucokinase activators led to a robust SAR in agreement

42 y by applying our methodology to a series of glucokinase activators that could be useful for treating

43 es on a carboxylic acid containing series of glucokinase activators with preferential activity in hep

44 that enhance SGU in diabetic patients (e.g. glucokinase activators) are likely to improve glucose to

45 novel bidentate anchor point for allosteric glucokinase activators.

46 atory evolution was conducted to improve the glucokinase activities of AlsK and NanK.

47 lypeptides, all of which possess rudimentary glucokinase activities.

48 Additionally, altered glucokinase activity affected release of the orexigenic

49 , resulting in diminished mitochondria-based glucokinase activity and blunted mitochondrial respirati

50 domain, significantly reduced both intrinsic glucokinase activity and glucose-induced insulin secreti

51 ents and may allow yeast to rapidly modulate glucokinase activity as nutrient availability changes.

52 Subsequent glucokinase activity assays of the glcK mutant further s

53 port that icv FGF1 injection increases liver glucokinase activity by approximately twofold.

54 This increase provides sufficient glucokinase activity for reconstitution of the defunct g

55 Lower glucokinase activity in GS-5 was associated with release

56 Together, our results suggest that glucokinase activity in the arcuate nucleus specifically

57 by hormones and metabolites of glucose, and glucokinase activity is dependent on reversible binding

58 in the alsK and nanK genes that improve the glucokinase activity of each enzyme.

59 e ingestion, while decreased arcuate nucleus glucokinase activity reduced glucose intake.

60 critical regulator of neuronal glucosensing, glucokinase activity was increased, using a glucokinase

61 In fasted rats, glucokinase activity was specifically increased in the a

62 Here, we determined that glucokinase activity within the hypothalamic arcuate nuc

63 on in MIN6 cells but had only some effect on glucokinase activity.

64 stimulation of HGU through increased hepatic glucokinase activity.

65 phosphorylation status of BAD helps regulate glucokinase activity.

66 Liver glucose metabolism is dependent on glucokinase activity.

67 Glucokinase acts as a glucose sensor in pancreatic beta

68 ic phosphofructokinases (ADP-PFKs), specific glucokinases (ADP-GKs), and bifunctional enzymes (ADP-PF

69 In this study, we present ADP-dependent glucokinase (ADPGK) as a novel glucose sensor and a pote

70 ADP-dependent glucokinase (ADPGK) catalyzes glucose-6-phosphate produc

71 asmic reticulum (ER)-localized ADP-dependent glucokinase (ADPGK) has been shown to play a critical ro

72 ted in granule fusion, also colocalized with glucokinase after hypotonic lysis or detergent extaction

73 nous insulin or gene transfer for insulin or glucokinase alone failed to achieve complete correction

74 To examine the role of glucokinase, an important CNS glucose sensor, we studied

75 a(+)-dependent secondary active transport, a glucokinase and enzymes of the pentose phosphate pathway

76 iched for the glucose phosphorylating enzyme glucokinase and for genes encoding other enzymes involve

77 uctase), while genes involved in glycolysis (glucokinase and glycerol kinase) were decreased in L-Fab

78 ted viral vectors of serotype 1 encoding for glucokinase and insulin in diabetic dogs resulted in nor

79 " in skeletal muscle through coexpression of glucokinase and insulin, increasing glucose uptake and c

80 t in human plasma, by side activities of ADP-glucokinase and low-K (M) hexokinases.

81 he shunt pathway, and lipogenesis, including glucokinase and SREBP-1c.

82 sulin-processing enzymes, beta-cell-specific glucokinase and sulfonylurea receptor.

83 r analyses confirmed the interaction between glucokinase and the ubiquitin-like domain in insulin-sec

84 ht into the evolutionary relationship of ROK glucokinases and non-ROK glucokinases (Pfam 02685), reve

85 due in part to reduced expression of hepatic glucokinase, and hyperammonemia from reduced expression

86 n of pancreatic duodenal hemeobox-1 (PDX-1), glucokinase, and insulin-1 was increased as a result of

87 retion pathway including PC1/3, PC2, GLUT-1, glucokinase, and K-ATP channel complex (Sur1 and Kir6.2)

88 activated receptor gamma coactivator 1 beta, glucokinase, and microsomal triacylglycerol transfer pro

89 ylase, fatty acid synthase, SREBP1c, chREBP, glucokinase, and pyruvate kinase.

90 ucose-sensing neurons (13.5%), which express glucokinase, and the selective urocortin 3 (UCN3) recept

91 erefore, it appears that K(ATP) channels and glucokinase are expressed in GnRH neurons, which renders

92 These results confirm the potency of glucokinase as the pancreatic beta-cell glucose sensor,

93 y implicated in mitochondrial recruitment of glucokinase, as a significant factor influencing the lev

94 s show glucose-responsive insulin secretion, glucokinase association with the granules and low-densit

95 e-2/fructose-2,6-bisphosphatase)/FDPase-2, a glucokinase-binding protein, and glyceraldehyde phosphat

96 hybrid library was produced and searched for glucokinase-binding proteins.

97 s enzyme, and a major unanswered question in glucokinase biology is how post-translational modificati

98 1-4 (Glut1-4), phosphoglycerate kinase 1 and Glucokinase but not of prolyl hydroxylase isoforms.

99 ases in the expression of the glucose sensor glucokinase, but decreases in that of two transcription

100 pc2 opposes the action of the glucose sensor glucokinase by hydrolyzing G6P.

101 sucrose gradient centrifugation showed that glucokinase colocalized with the granule membrane marker

102 results provide the first direct evidence of glucokinase conformational heterogeneity and hence shed

103 optotic BCL-2 family member BAD resides in a glucokinase-containing complex that regulates glucose-dr

104 Polyphosphate glucokinase converts glucose to glucose-6-phosphate usin

105 est that structural rearrangements linked to glucokinase cooperativity involve a substrate-induced re

106 f these mechanisms is sufficient to describe glucokinase cooperativity, a transient-state kinetic ana

107 neurons in the ventromedial hypothalamus in glucokinase-Cre mice, which express Cre in glucose-sensi

108 Genetic selection experiments in a glucokinase-deficient bacterium identified a variety of

109 bined with in vivo functional selection in a glucokinase-deficient bacterium to identify four indepen

110 ited to provide new functions, we placed the glucokinase-deficient bacterium under selection for grow

111 f the alsK gene relieves the auxotrophy of a glucokinase-deficient bacterium, demonstrating that weak

112 he loop, coupled with genetic selection in a glucokinase-deficient bacterium, uncovers a hyperactive

113 sensing is conventionally thought to involve glucokinase-dependent metabolism of glucose to ATP, whic

114 glucose-6-phosphatase and the repression of glucokinase during fasting, thus increasing lipogenesis

115 rmacologic targeting of potential downstream glucokinase effectors revealed that ATP-sensitive potass

116 -d-mannosamine are largely unaffected by the glucokinase-enhancing substitutions.

117 lar signaling of adult tissues and regulates glucokinase enzyme activity in pancreatic beta cells.

118 re glucokinase positive, and the identity of glucokinase-expressing cells remains to be determined.

119 -sensing region that contains characteristic glucokinase-expressing glucose-sensing neurons that resp

120 IRS-1 was also associated with a decrease in glucokinase expression and a trend toward increased bloo

121 In humans, changes in glucokinase expression and activity are associated with

122 hepatic glucose recycling via suppression of glucokinase expression in the basal state to preserve he

123 Glucokinase expression is transcriptionally regulated by

124 , reduced expression of PEPCK, and increased glucokinase expression resulting in reduced hepatic gluc

125 d gluconeogenic enzymes is impaired, hepatic glucokinase expression, incorporation of 14C-glucose int

126 oncomitant upregulation of islet insulin and glucokinase expression.

127 glucose metabolism revealed that the hepatic glucokinase flux was decreased by 95% in L-G6pc(-/-) mic

128 found that Glk1, a Saccharomyces cerevisiae glucokinase, forms two-stranded filaments with ultrastru

129 were expressed as glutathionyl S-transferase-glucokinase fusion proteins.

130 Glucokinase (GCK) and glucose-6-phosphatase catalytic su

131 s of hepatic glucose fluxes revealed reduced glucokinase (GCK) and glycogen synthase fluxes as compar

132 nantly nuclear protein that inhibits hepatic glucokinase (GCK) and plays a critical role in glucose h

133 Glucokinase (GCK) catalyzes the rate-limiting step of gl

134 Mutations in the gene encoding glucokinase (GCK) cause a mild hereditary form of diabet

135 Mutations in glucokinase (GCK) cause a spectrum of glycemic disorders

136 Glucokinase (GCK) controls the rate of glucose metabolis

137 Glucokinase (Gck) is a critical regulator of glucose-ind

138 Human glucokinase (GCK) is the prototypic example of an emergi

139 Patients with heterozygous, inactivating glucokinase (GCK) mutations have mild fasting hyperglyce

140 as been useful for identifying patients with glucokinase (GCK) mutations which cause lifelong persist

141 Glucokinase (GCK) regulates glucose storage and disposal

142 Mice haploinsufficient for beta cell glucokinase (Gck) were unable to increase their beta cel

143 messenger RNA (mRNA) expression of KLF6 and glucokinase (GCK), as an important mediator of insulin s

144 (egr-1), involved in mitogenic response, and glucokinase (Gck), encoding a key metabolic enzyme.

145 Cooperativity in human glucokinase (GCK), the body's primary glucose sensor and

146 (K140E) and Gck(P417R)) in the gene encoding glucokinase (Gck), the mammalian glucose sensor that is

147 The hallmark of glucokinase (GCK), which catalyzes the phosphorylation o

148 d intravenous glucose loads in patients with glucokinase (GCK)-diabetes (MODY2) and hepatocyte nuclea

149 ditional subjects with HNF1A-MODY (n = 188), glucokinase (GCK)-MODY (n = 118), hepatocyte nuclear fac

150 s AKT and Foxo1, and decreased expression of glucokinase (Gck).

151 istent with post-translational activation of glucokinase (GCK).

152 thway culminating in induction of the enzyme glucokinase (GCK).

153 determinant of fasting glucose is the enzyme glucokinase (GCK).

154 zygous loss of function of the gene encoding glucokinase (GCK).

155 glucose, in line with decreases in Glut2 and glucokinase gene expression, and attenuated glucose-stim

156 ng that icv FGF1 treatment increases hepatic glucokinase gene expression, we considered the possibili

157 A previously proposed hypothesis that the glucokinase gene might be expressed in the pituitary cor

158 stimulated insulin secretion, illustrated by glucokinase gene mutations causing monogenic diabetes an

159 ehensive analysis of common variation of the glucokinase gene shows that this is the first gene to be

160 e transcription but blunted the induction of glucokinase gene transcription and completely blocked th

161 tagenesis screen identified glcK, a putative glucokinase gene, required for beta-d-allose-mediated in

162 to T transversion mutation in exon 9 of the glucokinase gene, resulting in an isoleucine to phenylal

163 Glucokinase (GK) activation as a potential strategy to t

164 Glucokinase (GK) activators are currently under investig

165 ucing glucose transporter type 2 (Glut2) and glucokinase (GK) activities.

166 ring VMH glucosensing by raising or lowering glucokinase (GK) activity failed to affect spontaneous f

167 Glucokinase (GK) activity plays a key role in glucose-st

168 ucose, hepatic glycogen content, and hepatic glucokinase (GK) activity/expression as well as higher e

169 gered an increase in the activity of hepatic glucokinase (GK) and glycogen synthase (GS), which occur

170 Glucokinase (GK) and its inhibitory protein, GK regulato

171 Glucokinase (GK) appears to be the primary regulator of

172 ized glucosensing neurons, many of which use glucokinase (GK) as the rate-limiting step in glucose's

173 However, overactivation of glucokinase (GK) can cause excessive glucose turnover, l

174 other virus expressing an siRNA specific for glucokinase (GK) caused 80% suppression of GK mRNA and 5

175 Glucose flux through glucokinase (GK) controls insulin release from the pancr

176 ty (ZDF) rats whether restoration of hepatic glucokinase (GK) expression would alter hepatic glucose

177 Mutations in the glucokinase (GK) gene cause defects in blood glucose hom

178 Glucokinase (GK) has several known polymorphic activatin

179 Glucokinase (GK) is a glucose sensor that couples glucos

180 Human glucokinase (GK) is a principal regulating sensor of pla

181 Glucokinase (GK) is hypothesized to be the critical gluc

182 Glucokinase (GK) is the rate-limiting step for insulin r

183 orted a novel approach to increase cytosolic glucokinase (GK) levels through the binding of a small m

184 trient sensing between beta-cells, including glucokinase (GK) levels, mitochondrial function, or expr

185 To better understand how glucokinase (GK) missense mutations associated with huma

186 The transient kinetics of glucose binding to glucokinase (GK) was studied using stopped-flow fluoresc

187 Small molecule activators of glucokinase (GK) were used in kinetic and equilibrium bi

188 Glucokinase (GK), a key enzyme that regulates glucose ho

189 ivity with glucose is a key feature of human glucokinase (GK), allowing its crucial role as a glucose

190 actate, and express both the glucose sensor, glucokinase (GK), and the SUR1 subunit of the plasma mem

191 Glucokinase (GK), the putative glucosensing gatekeeper,

192 d expression of the GalP permease (galP) and glucokinase (glk).

193 that GI and GE, but not NR, cells expressed glucokinase (GLK).

194 The glucokinase-glucokinase regulatory protein (GK-GKRP) com

195 mide (51) that was a potent disruptor of the glucokinase-glucokinase regulatory protein (GK-GKRP) int

196 A nonracemic synthesis of the glucokinase-glucokinase regulatory protein disruptor AMG

197 Purified glucokinase had a monomeric molecular mass of 33.8kDa wh

198 Heterozygous activating mutations of glucokinase have been reported to cause hypoglycemia att

199 Small molecule activators of glucokinase have shown robust efficacy in both preclinic

200 an important CNS glucose sensor, we studied glucokinase-heterozygous knockout mice, but found that t

201 , adenosine deaminase complexing protein 2); glucokinase (hexokinase 4) regulator; guanylate cyclase

202 We report three children with de novo glucokinase hyperinsulinism mutations who displayed a sp

203 iveness to diazoxide varies with genotype in glucokinase hyperinsulinism resulting in hypoglycemia, w

204 In one case, an activating mutation of glucokinase (I211F) was found in pathological islets onl

205 ther, these data support a critical role for glucokinase in neuronal glucosensing.

206 cleus and cytoplasm and co-localization with glucokinase in pancreatic beta cells.

207 inant human glucokinase in vitro and also of glucokinase in target cells.

208 ver, pharmacologic and genetic activation of glucokinase in the arcuate nucleus of rodent models incr

209 -saccharides that involve the glucose-PTS or glucokinase in their catabolism.

210 the catalytic activity of recombinant human glucokinase in vitro and also of glucokinase in target c

211 The glucokinase inhibitor alloxan increases KATP single-chan

212 orexin cell glucose sensing is unaffected by glucokinase inhibitors alloxan, d-glucosamine, and N-ace

213 In contrast, infusion of the glucokinase inhibitors glucosamine or mannoheptulose wor

214 olarization and inhibition are unaffected by glucokinase inhibitors such as alloxan, D-glucosamine, a

215 stent with their documented insensitivity to glucokinase inhibitors, the glucose responses of orexin

216 Expression of the mutant glucokinase ins454A, W99L, and M197I enzymes revealed a

217 The secretin, beta-glucokinase, insulin I, and insulin II genes, four known

218 nd hPXR mice exhibited impaired induction of glucokinase involved in glucose utilization and displaye

219 To test the hypothesis that glucokinase is a critical regulator of neuronal glucosen

220 Glucokinase is a key regulator of glucose homeostasis, a

221 Because glucokinase is a metabolic sensor involved in the regula

222 Human glucokinase is a monomeric enzyme that displays a sigmoi

223 Human pancreatic glucokinase is a monomeric enzyme that displays kinetic

224 The results suggest that glucokinase is an integral component of the granule and

225 nt of GKRP with altered binding affinity for glucokinase is associated with increased blood and liver

226 Glucokinase is inhibited in the postabsorptive state by

227 g that the synergistic action of insulin and glucokinase is needed for full therapeutic effect.

228 Glucokinase is one of the promising targets for glucose-

229 we show that the pancreatic isoform of human glucokinase is SUMOylated in vitro, using recombinant en

230 ucose is metabolized in alpha-cells and that glucokinase is the likely rate-limiting step in this pro

231 Glucokinase is the predominant hexokinase expressed in h

232 mechanistically, as the FOXO1 corepressor of glucokinase is unknown, and clinically, as inhibition of

233 Intracellular Mg(2+) regulates glucokinase, KATP channels, and L-type Ca(2+) channels i

234 rol subjects (euinsulinemia and euglycemia), glucokinase-maturity-onset diabetes of the young (GCK-MO

235 /Q calcium channel activity are required for glucokinase-mediated glucose intake.

236 Impaired glucokinase-mediated glucose phosphorylation in LRH-1-de

237 It is also the first glucokinase missense mutation reported in mice and is ho

238 However, glucokinase mRNA and protein levels as well as fructose-

239 ary VMH neuronal cultures, the expression of glucokinase mRNA and the number of demonstrable glucosen

240 e RNA did not affect survival but did reduce glucokinase mRNA by 90% in association with loss of all

241 IL-6 also decreased refeeding-dependent glucokinase mRNA induction by approximately 40%.

242 o, a subpopulation of GnRH neurons expressed glucokinase mRNA, a marker for glucose sensitivity.

243 re observed in mice expressing an activating glucokinase mutation, in in vitro models of hyperglycaem

244 relationship of ROK glucokinases and non-ROK glucokinases (Pfam 02685), revealing the primary sequenc

245 substitutions colocalize to a region of the glucokinase polypeptide where a synthetic allosteric act

246 No evidence was found that corticotrophs are glucokinase positive, and the identity of glucokinase-ex

247 In siACC1-treated cells, glucokinase protein levels were decreased by 25%, which

248 cterized by high activities of fructokinase, glucokinase, pyruvate kinase, and tricarboxylic acid cyc

249 ation optimized spectra of uniformly labeled glucokinase, recorded in the absence and presence of glu

250 yltransferase domain-containing (MBOAT), and glucokinase regulator (CGKR) genes.

251 transmembrane 6 superfamily member 2), GCKR (glucokinase regulator), and HCC in patients treated with

252 bound O-acyltransferase domain containing 7, glucokinase regulator, and hydroxysteroid 17-beta dehydr

253 GCKR (glucokinase regulator; P=9.8x10(-10)) and HIF1AN (factor

254 riation in the apolipoprotein A5 (APOA5) and glucokinase regulatory protein (GCKR) genes has been ass

255 Glucokinase regulatory protein (GCKR) inhibitors offer a

256 nfirmed association of a SNP in an intron of glucokinase regulatory protein (GCKR) with serum triglyc

257 (NCAN), lysophospholipase-like 1 (LYPLAL1), glucokinase regulatory protein (GCKR), and protein phosp

258 rphism (SNP) identified as rs1260326, in the glucokinase regulatory protein (GCKR), was associated wi

259 ese activators relieved GK's inhibition from glucokinase regulatory protein (GKRP) in a glucose-depen

260 nity and/or by alleviating the inhibition of glucokinase regulatory protein (GKRP), a key regulator o

261 GCKR encodes glucokinase regulatory protein (GKRP), a predominantly n

262 glucokinase to a specific inhibitor protein, glucokinase regulatory protein (GKRP), and to other bind

263 by targeting the endogenous inhibitor of GK, glucokinase regulatory protein (GKRP).

264 small molecule to its endogenous inhibitor, glucokinase regulatory protein (GKRP).

265 the liver where its activity is regulated by glucokinase regulatory protein (GKRP; gene name GCKR).

266 1.12-1.21; P = 2.24 x 10(-10)), rs1260326 in glucokinase regulatory protein (OR, 1.12; 95% CI, 1.07-1

267 Allosteric responses to inhibition by glucokinase regulatory protein and activation by the dru

268 , prevented inhibition of enzyme activity by glucokinase regulatory protein and corresponded with red

269 The glucokinase regulatory protein encoded by GCKR plays an

270 st the stabilizing protein interactions with glucokinase regulatory protein, which may contribute to

271 LD hepatocytes and inversely correlates with glucokinase regulatory protein, which negatively regulat

272 Disruption of the glucokinase regulatory protein-binding site (GCK(K140E))

273 lucokinase activator drug, and the effect of glucokinase regulatory protein.

274 vestigated these issues using GCKR, encoding glucokinase regulatory protein.

275 ermeabilization with digitonin, 50% of total glucokinase remained bound intracellularly, while 30% wa

276 insulin secretion, glucose or inhibitors of glucokinase, respectively, were infused into the third v

277 ndent activation of G6pase and inhibition of glucokinase, respectively.

278 rocarbon-stapled BAD BH3 helices that target glucokinase, restore glucose-driven mitochondrial respir

279 ansfection of neurons with small interfering glucokinase RNA did not affect survival but did reduce g

280 r fetal growth, the -30G-->A polymorphism of glucokinase (rs1799884).

281 kinetic model presented herein suggests that glucokinase samples multiple conformations in the absenc

282 x alpha13 and the functional dynamics of the glucokinase scaffold that are required for allostery.

283 They also identify novel features of the glucokinase scaffold that could be targeted during the d

284 Glucokinase steady-state kinetics is unaffected by the e

285 se (3-MG), which cannot be phosphorylated by glucokinase, stimulate TXNIP expression.

286 compete strongly with glucose for binding to glucokinase, the key glycolysis enzyme presumably active

287 Ligand binding to glucokinase, thrombin, and its precursor prethrombin-2 a

288 tivity is dependent on reversible binding of glucokinase to a specific inhibitor protein, glucokinase

289 The glucokinase V62M and G72R mutations are naturally occurr

290 Unexpectedly, the K(m glucose) value of a glucokinase variant lacking alpha13 is equivalent to the

291 n Pten(+/-) mice, hepatic gene expression of glucokinase was 10-fold less than wild-type (Pten(+/+))

292 Enzymatic activity of glucokinase was demonstrated, quantitated, and character

293 ctionation of the organelles, immunoreactive glucokinase was distributed approximately equally betwee

294 mulate hepatic glucose uptake; activation of glucokinase was restored and insulin action was improved

295 on of the insulin-responsive GLUT 4, but not glucokinase, was reduced by 30% in NIRKO mice while regi

296 c glucose sensing protein expression (GLUTs, glucokinase) were measured.

297 The association of glucokinase with insulin secretory granules has been sho

298 Inhibition of glucokinase with mannoheptulose or 5-thioglucose selecti

299 F, and YcfX proteins function as rudimentary glucokinases with ambiguous substrate specificites, disp

300 on of SIN3A abolishes nutrient regulation of glucokinase without affecting other FOXO1 target genes a